Zynerba Press Releases

13 Mar 17 Zynerba Pharmaceuticals Announces Completion of Enrollment for ZYN002 in Two Phase 2 Clinical Trials for Epilepsy and Osteoarthritis

1 Mar 17 Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences

9 Feb 17 Zynerba Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

19 Jan 17 Zynerba Pharmaceuticals Announces Pricing of Public Offering of Common Stock

18 Jan 17 Zynerba Pharmaceuticals Announces Proposed Public Offering of Common Stock

3 Jan 17 Zynerba Pharmaceuticals Announces Initiation of the FAB-C Exploratory Phase 2 Clinical Trial of ZYN002 CBD Gel in Patients with Fragile X Syndrome

8 Dec 16 Zynerba Pharmaceuticals to Host Clinical Research Day on December 15, 2016 to Discuss the Role of ZYN002 CBD Gel in Multiple Diseases

5 Dec 16 Zynerba Reports Positive Results for ZYN002 CBD Gel in Phase 1 Studies at 70th Annual Meeting of the American Epilepsy Society

28 Nov 16 Zynerba Pharmaceuticals to Highlight Data for ZYN002 CBD Gel at the 70th Annual Meeting of the American Epilepsy Society

21 Nov 16 Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences